This is a preview of subscription content, log in via an institution to check access.
Notes
2015 US dollars
Reference
Gilligan AM, et al. All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin. American Journal of Cardiovascular Drugs : 9 Aug 2017. Available from: URL: http://doi.org/10.1007/s40256-017-0244-1
Rights and permissions
About this article
Cite this article
Dabigatran saves healthcare costs in patients with NVAF. PharmacoEcon Outcomes News 785, 9 (2017). https://doi.org/10.1007/s40274-017-4259-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4259-2